Science

Mar 11, 2025, 09:16

Myeloma Paper of the Day, March 11th, suggested by Robert Orlowski

Robert Orlowski, Florence Maude Thomas Cancer Research Professor at the University of Texas MD Anderson Cancer Center, shared a post on X:

“Myeloma Paper of the Day: Phase II of zanubrutinib + ixazomib/dex in newly diagnosed Waldenström macroglobulinemia finds 4.2% CR and 41.6% VGPR rates; overall, major and deep remission rates 100%, 95.8% and 45.8%; median PFS and OS 40 mos and not reached.”

“Zanubrutinib plus Ixazomib and Dexamethasone in newly diagnosed symptomatic Waldenström macroglobulinemia:a phase II study”

Authors: Wenjie Xiong, Yuting Yan, Tingyu Wang, Lugui Qiu, Shuhua Yi et al.

More posts featuring Robert Orlowski.

cancer ixazomib Lugui Qiu Myeloma Paper of the Day OncoDaily Oncology Robert Orlowski Shuhua Yi Tingyu Wang Waldenström macroglobulinemia Wenjie Xiong Yuting Yan Zanubrutinib

Padraic O’Malley: Meet the Experts of VIRO 2025

Hidden Risks: BRCA Mutations and Breast Implants - CancerWorld

FDA Breakthrough Therapy Designation for Iza-bren: Advancing Treatment for EGFR-Mutant NSCLC

Neil Ranasinghe: What’s the Difference Between a Clinician and a Technical Author?

LOCKTAC Molecular Glues Are Changing the Rules of Drug Discovery - Amgen